FOR RESEARCH USE ONLY
Established clinical literatureMetabolic research

Tirzepatide

Dual GIP / GLP-1 receptor agonist with class-leading weight and glycaemic outcomes (SURMOUNT / SURPASS).

01Dual incretin signalling02Glycaemic outcomes03Cardiometabolic research
Molecular signature / tirzepatide
Structural identity

39-amino-acid dual incretin receptor agonist

Also known as

LY-3298176 · GIP / GLP-1 receptor agonist

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Tirzepatide (LY-3298176) is a 39-amino-acid synthetic dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Marketed as Mounjaro (T2D) and Zepbound (obesity), it produces class-leading weight loss and glycaemic outcomes — adding GIP receptor activity to the established GLP-1 pathway for amplified incretin effect and improved adipocyte lipid handling.

The research question

Tirzepatide engages both GIP and GLP-1 receptors, creating a dual-incretin profile with sustained exposure. Research interpretation includes gastrointestinal tolerability, nutritional adequacy and the composition of weight change alongside primary endpoints.

Section 02

Mechanism & research themes

Balanced agonism of GIP receptors (incretin amplification, adipocyte lipid metabolism, neutral-to-positive insulin sensitivity effects) and GLP-1 receptors (glucose-dependent insulin secretion, glucagon suppression, satiety, delayed gastric emptying). Albumin-binding C20 fatty acid chain enables once-weekly dosing.

01

20.9% mean weight reduction at 15mg/week over 72 weeks (SURMOUNT-1, NEJM 2022)

02

HbA1c reductions of 1.8–2.4% vs placebo (SURPASS program)

03

Improvements across triglycerides, LDL, blood pressure and hepatic fat

04

Superior weight and glycaemic outcomes vs semaglutide head-to-head (SURMOUNT-5, 2024)

05

Cardiovascular and renal protective signals under active investigation

06

NASH resolution and MACE reduction trials ongoing

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Established clinical literature

Large randomised trials cover glycaemic and weight outcomes, with further cardiovascular and renal work ongoing. Trial results remain specific to studied doses, formulations and populations.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Standard titration: 2.5mg weekly (weeks 1–4) → 5mg (weeks 5–8) → 7.5mg → 10mg → 12.5mg → 15mg weekly maintenance, escalating every 4 weeks based on tolerability. Subcutaneous (abdomen, thigh, upper arm). Research protocols typically 24–72 weeks.

Reported persistence

approximately 120 hours (approximately 5 days), supporting once-weekly dosing.

Calculator starting point

2.5 mg per reference dose

1 doses per week · 16-week cycle

2 mL default reconstitution volume

Titrate: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, ~4 weeks at each step.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Tirzepatide
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 10mg vial with 2mL bacteriostatic water for a 5mg/mL working concentration. Swirl gently — do not shake. Allow to sit 2–3 minutes before use.

Storage reference

Lyophilised: 2–8°C, stable 24–36 months frozen. Reconstituted: 2–8°C, do not freeze, use within 28 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

GI side effects (nausea, vomiting, diarrhoea, constipation) reported in 40–60% of trial participants — dose-dependent.

L2

Lean mass loss accompanies weight loss — resistance training and adequate protein intake are critical.

L3

Class-level warnings include pancreatitis, gallbladder disease and gastroparesis; thyroid C-cell tumour boxed warning extrapolated from rodent data.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only